CVS surgery would provide little if any relief
The author is a Reuters Breakingviews columnist. The opinions expressed are his own.
By Robert Cyran
NEW YORK, Oct 1 (Reuters Breakingviews) -It’s easier to diagnose what ails CVS Health CVS.N than it is to prescribe a cure. Multiple profit warnings from the $78 billion healthcare conglomerate have raised doubts about its strategy. It may now be considering a breakup, but such radical surgery probably would bring little if any relief.
The company’s flagship drugstore chain is one painful problem. Insurance providers have been squeezing pharmacists as online marketplaces such as Amazon.com AMZN.O, mail-order rivals and big retailers including Walmart WMT.N muscle into the business. This competition is a big reason why CVS has generated a dismal 2% total shareholder return, including reinvested dividends, since 2015. It’s only slightly comforting that peer Rite Aid went bankrupt and Walgreen Boots Alliance WBA.O shareholders lost 80% of their investment over the same 10-year span.
CVS avoided an equally disastrous fate by diversifying. It paid $70 billion for insurer Aetna in 2018, following up with the $11 billion acquisition of primary care provider Oak Street and an $8 billion deal for Signify Health, which tends to patients at home. The M&A binge has been of dubious value, however. The combined purchase prices exceed the company’s current market capitalization, and it is now larded with $50 billion of net debt, twice as much as before the acquisitions, at nearly 5 times expected 2025 EBITDA, according to estimates gathered by LSEG.
Moreover, the latest struggles at CVS have centered around insurance. Boss Karen Lynch expanded the Medicare Advantage business, under which private insurers are paid by the U.S. government to manage healthcare benefits for retirees, at just the wrong time. Customers started using it more than expected while federal officials cracked down on reimbursements.
Carving up the company is now under consideration as part of a possible strategic shakeup, according to Reuters, amid pressure from at least one investor, per the Wall Street Journal. Its insurance business and ancillary services would generate $10 billion of adjusted operating profit this year, assuming second-half results match the first half. Rival Cigna CI.N trades at 10 times, implying Aetna-plus would be worth $100 billion.
Double the retail arm’s $2.4 billion of operating profit through June and put it on the same 9 times multiple commanded by Walgreens, and it would be worth nearly $45 billion. Together, the implied uplift for the enterprise would only be about 10%, including debt, which hardly justifies the risky operation. A better prescription for Lynch would be to stop doing overpriced deals and instead find ways to nurse the wounded units back to health.
Follow @rob_cyran on X
CONTEXT NEWS
CVS Health is exploring strategic options including breaking up the company by separating its pharmacy and insurance units, Reuters reported on Sept. 30, citing unnamed sources.
Hedge fund Glenview Capital has built a 1% stake in the company, according to an article published on the same day by the Wall Street Journal.
CVS shares have gone nowhere for a decade https://reut.rs/3Y54DNq
Editing by Jeffrey Goldfarb and Pranav Kiran
Aloqador aktivlar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
